Recent cancer treatment applications of immunotherapy include chimeric antigen receptor T cells, vaccine therapy, and immune checkpoint blockers (ICBs) targeting programmed cell death-ligand 1/programmed death protein 1 (PD-L1/PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) (4). This evidence concerns the gene CTLA4 and cancer.